Tag: British American Tobacco

  • Tobacco Firms Recognized as Top Employers

    Tobacco Firms Recognized as Top Employers

    BAT, Japan Tobacco International and Imperial Brands have been named as top employers by the Top Employers Institute.

    “Being named as a Global Top Employer for the fifth year in a row is a recognition of BAT’s inclusive, engaging culture and innovative working environment,” said Hae In Kim, director of talent, culture and inclusion at BAT, in a statement. “We are continually striving to maintain a workplace where employees feel empowered and well supported, and we are delighted this has been recognized.

    “It is an honor to once again be certified by Top Employers Institute,” said Howard Parks, JTI’s senior vice president of people and culture, in a press note. “Our people are at the heart of everything we do, which is why we aim to offer them the best possible working environment. Giving our over 40,000 colleagues the opportunity to grow and providing them with the optimal conditions and support to fulfil their potential is of paramount importance to us.”

    “I am delighted that Imperial has been recognized as a Top Employer for another year,” said Alison Clarke, Imperial’s chief people and culture officer, in a statement. “Imperial Brands is a great place to work, grow and develop, and it’s particularly pleasing that—in these challenging times when we can’t always congregate in the way we would like—our people have shown real resilience and embraced new ways of engaging to create an even better place to work.”

    The Top Employer certification process is conducted annually by the Top Employers Institute, an independent organization that studies the employee offerings of major employers around the world. Certification recognizes employers that provide best-in-class employment practices, allowing employees to develop themselves personally and professionally while driving business results. Participating companies undergo a rigorous assessment process, which includes an extensive review of employer practices. Several validation sessions are held where evidence of these practices is provided, and an independent audit of the findings is also carried out.

  • BAT Launches Virtual R&D Visitor Experience

    BAT Launches Virtual R&D Visitor Experience

    Image: BAT

    BAT has created a virtual R&D visitor experience, an online tour of its global research and development hub in Southampton, U.K., that allows people to explore its cutting-edge science and innovation.

    BAT says the experience builds on the company’s open and transparent approach to the science underpinning its reduced-risk product portfolio and beyond nicotine activities. The company regularly welcomes visitors in person to its global R&D hub, with more than 3,500 people viewing the facilities firsthand since 2011. However, with travel significantly reduced, the virtual experience allows people from across the globe to access and understand BAT’s scientific research and tobacco harm reduction activities and gain perspectives and insights from experts.

    “At BAT, R&D is fundamental to what we do,” said David O’Reilly, director of scientific research at BAT, in a statement. “Our focus on science and research has enabled us to make significant progress in developing and evolving our New Category products, which are rigorously tested and scientifically substantiated as reduced-risk alternatives to cigarettes. Our R&D is based around consumer preferences as well as applying evolving science and innovation to our products. This allows us to offer a range of enjoyable reduced-risk alternatives to cigarettes while ensuring we maintain very high safety and quality standards.

    “Our new R&D virtual visitor experience demonstrates the breadth of science we are undertaking and the robust scientific framework we use to evaluate and support the role our products play in delivering tobacco harm reduction.”

    With 360-degree lab tours, animations, videos, scientist profiles, podcasts and more, the R&D virtual visitor experience is the one-stop hub for those looking to find out about BAT’s science. The tour illuminates BAT’s purpose to build “A Better Tomorrow” and mission to reduce the health impact of its business. BAT invests almost £350 million [$477.18 million] a year to find innovative ways to reduce its effects on public health and aims to have 50 million consumers of its noncombustible products by 2030.

  • Daily Beast: BAT Backing Vape Group

    Daily Beast: BAT Backing Vape Group

    Photo: freshidea

    British American Tobacco is the driving force behind the World Vapers Alliance (WVA), a pro-vaping group presenting itself as a grassroots initiative of anti-smoking initiatives, according to the Daily Beast.

    According to the investigation, BAT sought to use the WVA to organize individuals to pressure government officials, including members of the European parliament, to roll back regulations on tobacco products such as bans on flavored products, health warnings and increased taxes. 

    BAT went to great lengths to conceal its involvement with the World Vapers’ Alliance, according to the investigation. Yet, sources and internal documents reviewed as part of the investigation revealed that BAT “has played a central and hands-on role in orchestrating, directing and funding the World Vapers’ Alliance.”

    Anti-smoking groups were aghast. “Tobacco companies like British American Tobacco claim that they are changed, responsible companies working to reduce the enormous harm caused by their products. But their actions tell a different story and show that they continue to use the same deceptive tactics they have always used, including front groups, to fight public health policies and protect their sales and profits,” said Matthew L. Myers, president of the Campaign for Tobacco-Free Kids, in a statement.

    Writing for Vaping360, Jim McDonald said BAT’s involvement with WVA was no secret among vaping advocates, “which is probably a major reason why the organization only has 20,000 individual members, despite extensive social media efforts,” he wrote.

    According to McDonald, many vapers tend to mistrust and resent involvement in vaping issues by the tobacco industry, partly because companies like BAT subsidiary Reynolds American Inc. have gone out of their way to eliminate the competition posed by independent vaping businesses.

    McDonald cites a 2014 RAI comment to the FDA, “essentially offering the agency a blue-print for destroying the open-system vaping industry.”

  • BAT Creates Plant-Based Technology Firm

    BAT Creates Plant-Based Technology Firm

    Photo: BAT

    BAT today announced the launch of KBio Holdings to accelerate the research, development and production of novel treatments. KBio will leverage the plant-based technology capabilities of BAT and Kentucky BioProcessing, BAT’s U.S. plant biologics organization.

    KBio will explore new opportunities to develop its plant-based production system, which has the potential to offer greater speed, scale-up opportunity and thermostability. The new company will focus on delivering treatments for rare and infectious diseases by realizing and expanding the potential of both the plant-based technology platform as well as its existing clinical and preclinical vaccines and antibody pipeline.

    KBio will look to form innovative R&D collaborations and financing aimed at expanding its pipeline and future portfolio, with an ambition of financial self-sufficiency.

    Supporting the company’s future plans, a standalone operational structure for KBio is being established. This includes building a new executive leadership team led by Patrick Doyle as the CEO of KBio. Doyle brings more than 20 years of experience leading innovative biotech companies.

    “I am excited by the opportunity to build on the significant accomplishments made by BAT and KBP,” said Doyle in a statement. “I am confident in the potential of KBio’s powerful plant-based platform, capabilities and emerging early-stage pipeline. To date, the technology has demonstrated its ability to produce novel antibody and vaccine candidates with high purity at a fraction of the time and cost of current technologies. The speed and efficiency demonstrated by the KBio platform has significant potential. This could enable us to progress to clinical studies faster than industry norms in the hope of delivering treatment solutions more quickly.”

    “Science and innovation are fundamental to BAT and delivering on our purpose of building ‘A Better Tomorrow,’” said David O’Reilly, BAT’s director of scientific research. “We recognize the potential of our innovative plant-based technology and have established KBio to maximize that potential. We are excited to see what the future holds.”